Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells

Biochemical and Biophysical Research Communications

Volumn 357, Issue 4, 2007, Pages 1166-1171

  Fukada, Kazuhiro ^a   Takahashi Yanaga, Fumi ^a   Sakoguchi Okada, Naoko ^a   Shiraishi, Fumie ^a   Miwa, Yoshikazu ^a   Morimoto, Sachio ^a   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cancer; Clecoxib; Nonsteroidal anti inflammatory drugs (NSAIDs); Promoter activity; Survivin

Indexed keywords

CASPASE 3; CELECOXIB; LUCIFERASE; MESSENGER RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CODON; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; GENE VECTOR; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE;

APOPTOSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 34247886162     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.077     Document Type: Article

References (29)

1. Raff M.C. Social controls on cell survival and cell death. Nature 356 (1992) 397-400
2. Huerta S., Goulet E.J., and Livingston E.H. Colon cancer and apoptosis. Am. J. Surg. 191 (2006) 517-526
3. Johnson M.E., and Howerth E.W. Survivin: a bifunctional inhibitor of apoptosis protein. Vet. Pathol. 41 (2004) 599-607
4. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6 (2000) 127-134
5. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., and Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92 (2001) 271-278
6. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58 (1998) 5071-5074
7. Song Z., Yao X., and Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem. 278 (2003) 23130-23140
8. Thun M.J., Namboodiri M.M., and Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325 (1991) 1593-1596
9. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94 (2002) 252-266
10. Ding X.Z., Tong W.G., and Adrian T.E. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20 (2000) 2625-2631
11. Kamijo T., Sato T., Nagatomi Y., and Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int. J. Urol. 8 (2001) 35-39
12. Kim S.H., Song S.H., Kim S.G., Chun K.S., Lim S.Y., Na H.K., Kim J.W., Surh Y.J., Bang Y.J., and Song Y.S. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J. Cancer Res. Clin. Oncol. 130 (2004) 551-560
13. Williams C.S., and DuBois R.N. Prostaglandin endoperoxide synthase: why two isoforms?. Am. J. Physiol. 270 (1996) 393-400
14. Williams C.S., Smalley W., and DuBois R.N. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest. 100 (1997) 1325-1329
15. Rozic J.G., Chakraborty C., and Lala P.K. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int. J. Cancer 93 (2001) 497-506
16. Cheng J., Imanishi H., Amuro Y., and Hada T. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer 99 (2002) 755-761
17. Maier T.J., Schilling K., Schmidt R., Geisslinger G., and Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67 (2004) 1469-1478
18. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
19. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., and Mukherjee P. Mechanisims underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 7 (2005) 422-435
20. Nakazono-Kusaba A., Takahashi-Yanaga F., Miwa Y., Morimoto S., Furue M., and Sasaguri T. PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts. Eur. J. Pharmacol. 497 (2004) 155-160
21. Takahashi-Yanaga F., Taba Y., Miwa Y., Kubohara Y., Watanabe Y., Hirata M., Morimoto S., and Sasaguri T. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3β and degrades cyclin D1 in mammalian cells. J. Biol. Chem. 278 (2003) 9663-9670
22. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., Morimoto S., Iida M., and Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol. 73 (2007) 1318-1329
23. Miyagi M., Miwa Y., Takahashi-Yanaga F., Morimoto S., and Sasaguri T. Activator protein-1 mediates shear stress-induced prostaglandin D synthase gene expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 970-975
24. Cui W., Yu C.H., and Hu K.Q. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin. Cancer Res. 11 (2005) 8213-8221
25. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., and Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
26. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3 (2003) 46-54
27. Zhao J., Tenev T., Martins L.M., Downward J., and Lemoine N.R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113 (2000) 4363-4371
28. Kim S.H., Hwang C.I., Park W.Y., Lee J.H., and Song Y.S. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 27 (2006) 1961-1969
29. Maier T.J., Janssen A., Schmidt R., Geisslinger G., and Grösch S. Targeting the β-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J. 19 (2005) 1353-1355